Pathophysiology of the basal ganglia in Parkinson's disease

J A Obeso; M C Rodríguez-Oroz; M Rodríguez; J L Lanciego; J Artieda; N Gonzalo; C W Olanow

doi:10.1016/s1471-1931(00)00028-8

Pathophysiology of the basal ganglia in Parkinson's disease

Trends Neurosci. 2000 Oct;23(10 Suppl):S8-19. doi: 10.1016/s1471-1931(00)00028-8.

Authors

J A Obeso¹, M C Rodríguez-Oroz, M Rodríguez, J L Lanciego, J Artieda, N Gonzalo, C W Olanow

Affiliation

¹ Dept of Neurology, Neuroscience Centre, Clinica Universitaria and Medical School, University of Navarra, Pamplona, Spain.

PMID: 11052215
DOI: 10.1016/s1471-1931(00)00028-8

Abstract

Insight into the organization of the basal ganglia in the normal, parkinsonian and L-dopa-induced dyskinesia states is critical for the development of newer and more effective therapies for Parkinson's disease. We believe that the basal ganglia can no longer be thought of as a unidirectional linear system that transfers information based solely on a firing-rate code. Rather, we propose that the basal ganglia is a highly organized network, with operational characteristics that simulate a non-linear dynamic system.

Publication types

Review

MeSH terms

Animals
Antiparkinson Agents / administration & dosage
Antiparkinson Agents / adverse effects*
Basal Ganglia / pathology
Basal Ganglia / physiopathology*
Disease Models, Animal
Dyskinesia, Drug-Induced / metabolism
Dyskinesia, Drug-Induced / physiopathology*
Dyskinesia, Drug-Induced / prevention & control
Humans
Levodopa / administration & dosage
Levodopa / adverse effects*
Models, Neurological
Neural Pathways
Neurons / metabolism
Parkinson Disease / metabolism
Parkinson Disease / physiopathology*
Pulse Therapy, Drug / adverse effects*
Receptors, Dopamine / metabolism

Substances

Antiparkinson Agents
Receptors, Dopamine
Levodopa